American Journal of Obstetrics & Gynecology
Volume 201, Issue 6 , Pages 553-559 , December 2009

In utero beta 2 adrenergic agonist exposure and adverse neurophysiologic and behavioral outcomes

  • Frank R. Witter, MD

      Affiliations

    • Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD
    • ,
  • Andrew W. Zimmerman, MD

      Affiliations

    • Department of Neurology and Developmental Medicine, Kennedy Krieger Institute, Johns Hopkins University School of Medicine, Baltimore, MD
    • Departments of Neurology, Psychiatry, and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD
    • Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD
    • ,
  • James P. Reichmann, MBA

      Affiliations

    • American Home Patient, Brentwood, TN
    • ,
  • Susan L. Connors, MD

      Affiliations

    • Department of Neurology and Developmental Medicine, Kennedy Krieger Institute, Johns Hopkins University School of Medicine, Baltimore, MD
    • LADDERS Clinic of Mass General Hospital and Harvard Medical School, Boston, MA

Received 9 June 2009 ,Revised 18 June 2009 ,Accepted 6 July 2009.

References 

  1. Cikos S, Veselá J, Il'ková G, Rehák P, Czikková S, Koppel J. Expression of beta adrenergic receptors in mouse oocytes and preimplantation embryos. Mol Reprod Dev. 2005;71:145–153
  2. Slotkin TA, Lau C, Seidler FJ. Beta-adrenergic receptor overexpression in the fetal rat: distribution, receptor subtypes, and coupling to adenylate cyclase activity via G-proteins. Toxicol Appl Pharmacol. 1994;129:223–234
  3. Crespo P, Cachero TG, Xu N, Gutkind JS. Dual effect of beta-adrenergic receptors on mitogen-activated protein kinase: evidence for a beta gamma-dependent activation and a G alpha s-cAMP-mediated inhibition. J Biol Chem. 1995;270:25259–25265
  4. Schmitt JM, Stork PJ. Beta 2 adrenergic receptor activates extracellular signal-related kinases (ERKs) via the small G protein rap1 and the serine/threonine kinase B-Raf. J Biol Chem. 2000;275:25342–25350
  5. Duncan CP, Seidler FJ, Lappi SE, Slotkin TA. Dual control of DNA synthesis by α- and β-adrenergic mechanisms in normoxic and hypoxic neonatal rat brain. Dev Brain Res. 1990;55:29–33
  6. Kwon JH, Eves EM, Farrell S, et al. Beta-adrenergic receptor activation promotes process outgrowth in an embryonic rat basal forebrain cell line and in primary neurons. Eur J Neurosci. 1996;8:2042–2055
  7. Gharami K, Das S. Thyroid hormone-induced morphological differentiation and maturation of astrocytes are mediated through the beta-adrenergic receptor. J Neurochem. 2000;75:1962–1969
  8. Slotkin TA, Auman JT, Seidler FJ. Ontogenesis of β-adrenoceptor signaling: implications for perinatal physiology and for fetal effects of tocolytic drugs. J Pharmacol Exp Ther. 2003;306:1–7
  9. Connors SL. Prenatal beta 2 adrenergic receptor signaling and autism: dysmaturation and retained fetal function. In:  Zimmerman AW editors. Autism: current theories and evidence. Totowa, NJ: Humana Press; 2008;p. 147–182
  10. Bergman B, Bokstrom H, Borga O, Enk L, Hedner T, Wangberg B. Transfer of terbutaline across the human placenta in late pregnancy. Eur J Respir Dis Suppl. 1984;134:81–86
  11. Hsu CH, Robinson CP, Basmadjian GP. Tissue distribution of 3H-terbutaline in rabbits. Life Sci. 1994;54:1465–1469
  12. Slotkin TA, Tate CA, Cousins MM, Seidler FJ. Beta-adrenoceptor signaling in the developing brain: sensitization or desensitization in response to terbutaline. Brain Res Dev Brain Res. 2001;131:113–125
  13. Meyer A, Seidler FJ, Aldridge JE, Slotkin TA. Developmental exposure to terbutaline alters cell signaling in mature rat brain regions and augments the effects of subsequent neonatal exposure to the organophosphorus insecticide chlorpyrifos. Toxicol Appl Pharmacol. 2005;203:154–166
  14. Rhodes MC, Seidler FJ, Abdel-Rahman A, et al. Terbutaline is a neurotoxicant: effects on neuroproteins and morphology in cerebellum, hippocampus, and somatosensory cortex. J Pharmacol Exp Ther. 2004;308:529–537
  15. Zerrate MC, Pletnikov M, Connors SL, et al. Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism. J Pharmacol Exp Ther. 2007;322:16–22
  16. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57:67–81
  17. Lam F, Elliott J, Jones JS, et al. Clinical issues surrounding the use of terbutaline sulfate for preterm labor. Obstet Gynecol Surv. 1998;53:S85–S95
  18. Goldenberg RL. The management of preterm labor. Obstet Gynecol. 2002;100:1020–1037
  19. Tegner K, Nilsson HT, Persson CG, Ryrfeldt A. Elimination pathways of terbutaline. Eur J Respir Dis Suppl. 1984;134:93–100
  20. Rice D, Barone S. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect. 2000;108(suppl 3):511–513
  21. Clancy B, Kersh B, Hyde J, Darlington RB, Anand KJS, Finlay BL. Web-based method for translating neurodevelopment from laboratory species to humans. Neuroinformatics. 2007;5:79–94
  22. Feldman DS, Elton TS, Sun B, Martin MM, Ziolo MT. Mechanisms of disease: detrimental adrenergic signaling in acute decompensated heart failure. Nat Clin Pract Cardiovasc Med. 2008;5:208–218
  23. El-Armouche A, Eschenhagen T. Beta-adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev. 2008 Dec 27;Epub ahead of print
  24. Del Colle S, Morello F, Rabbia F, et al. Antihypertensive drugs and the sympathetic nervous system. J Cardiovasc Pharmacol. 2007;50:487–496
  25. Ming X, Julu POO, Brimacombe M, Connor S, Daniels ML. Reduced cardiac parasympathetic activity in children with autism. Brain Dev. 2005;27:509–516
  26. Garofolo MC, Seidler FJ, Auman JT, Slotkin TA. Beta-adrenergic modulation of muscarinic cholinergic receptor expression and function in developing heart. Am J Phys Reg Integ Compar Physiol. 2002;282:R1356–R1363
  27. Stern MT, Parker S, Coplan J, Feldman H. Expressive language delay in a toddler. Pediatrics. 2001;107:905–909
  28. Connors SL, Crowell DE, Eberhart CG, et al. Beta 2-adrenergic receptor activation and genetic polymorphisms in autism: data from dizygotic twins. J Child Neurol. 2005;20:876–884
  29. Thrasher JD, Kilburn KY, Immers IB. Autism, terbutaline and neurological impairment: Ramazzi Days 2007: 25th Anniversary Jubilee, Capri Italy. CR Online Journal www.collegiumramazzini.orgAccessed Dec. 15, 2008
  30. Croen LA, Grether JK, Yoshida CK, Odouli R, Van de Water J. Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. Arch Pediatr Adolesc Med. 2005;159:151–157
  31. Pitzer M, Schmidt MH, Esser G, Laucht M. Child development after maternal tocolysis with beta-sympathomimetic drugs. Child Psychiatry Hum Dev. 2001;31:165–182
  32. Hadders-Algra M, Touwen BC, Huisjes HJ. Long-term follow-up of children prenatally exposed to ritodrine. BJOG. 1986;93:156–161
  33. Alvarez M, Pita S, Costas E, et al. Long term effects of ritodrine on blood pressure and heart rate of adolescents exposed during the prenatal stage. Eur J Obstet Gynecol Reprod Biol. 1995;59:137–141
  34. Brazy JE, Eckerman CO, Gross SJ. Follow-up of infants of less than 1500 gm birth weight with antenatal isoxsuprine exposure. J Pediatr. 1983;102:611–613
  35. Polowczyk D, Tejani N, Lauersen N, Siddiq F. Evaluation of seven- to nine-year-old children exposed to ritodrine in utero. Obstet Gynecol. 1984;64:485–488
  36. Freysz H, Willard D, Lehr A, Messer J, Boog G. A long term evaluation of infants who received a beta-mimetic drug while in utero. J Perinat Med. 1977;5:94–99
  37. Svenningsen NW. Follow-up studies on preterm infants after maternal beta-receptor agonist treatment. Acta Obstet Gynecol Scand Suppl. 1982;108:67–70
  38. Cockcroft JR, Gazis AG, Cross DJ, et al. Beta(2)-adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension. 2000;36:371–375
  39. Dishy V, Sofowora GG, Xie HG, et al. The effect of common polymorphisms of the beta 2 -adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med. 2001;345:1030–1035
  40. Green SA, Rathz DA, Schuster AJ, Liggett SB. The Ile 164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Eur J Pharmacol. 2001;421:141–147
  41. Lee DK, Currie GP, Hall IP, Lima JJ, Lipworth BJ. The arginine-16 beta 2-adrenoceptor polymorphism predisposes to broncho protective sub sensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol. 2004;57:68–75
  42. Pinelli M, Giacchetti M, Acquaviva F, et al. Beta 2 -adrenergic receptor and UCP3 variants modulate the relationship between age and type 2 diabetes mellitus. BMC Med Genet. 2006;7:85
  43. Liggett SB, Wagoner LE, Craft LL, et al. The Ile 164 beta 2 adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest. 1998;102:1534–1539
  44. Wolk R, Snyder EM, Somers VK, Turner ST, Olson LJ, Johnson BD. Arginine 16 glycine beta 2-adrenoceptor polymorphism and cardiovascular structure and function in patients with heart failure. J Am Soc Echocardiogr. 2007;20:290–297
  45. Jazdzewski K, Bednarczuk T, Stepnowska M, et al. Beta-2 adrenergic receptor gene polymorphism confers susceptibility to Graves disease. Int J Mol Med. 2007;19:181–186
  46. Xu BY, Huang D, Pirskanen R, Lefvert AK. Beta 2 -adrenergic receptor gene polymorphisms in myasthenia gravis (MG). Clin Exp Immunol. 2000;119:156–160
  47. Xu BY, Arlehag L, Rantapää-Dahlquist SB, Lefvert AK. Beta 2-adrenergic receptor gene single-nucleotide polymorphisms are associated with rheumatoid arthritis in northern Sweden. Scand J Rheumatol. 2004;33:395–398
  48. Kawaguchi H, Masuo K, Katsuya T, et al. Beta 2 - and beta3-adrenoceptor polymorphisms relate to subsequent weight gain and blood pressure elevation in obese normotensive individuals. Hypertens Res. 2006;29:951–959
  49. Busjahn A, Freier K, Faulhaber HD, et al. Beta 2 adrenergic receptor gene variations and coping styles in twins. Biol Psychol. 2002;61:97–109
  50. Cheslack-Postava K, Fallin MD, Avramopoulos D, et al. Beta 2-adrenergic receptor gene variants and risk for autism in the AGRE cohort. Mol Psychiatry. 2007;12:283–291
  51. National Institutes of Health. National asthma education report of the working group on asthma and pregnancy: management of asthma during pregnancy, recommendation for pharmacologic treatment update 2004. Bethesda, MD: National Institutes of Health; 2005;
  52. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM SMART Study Group. The salmeterol multicenter asthma research trial. Chest. 2006;129:15–26
  53. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006;144:904–912
  54. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events (review). Cochrane Database System Rev. 2008;3:CD006363
  55. Pollard SJ, Spector SL, Yancey SW, Cox FM, Emmett A. Salmeterol versus theophylline in the treatment of asthma. Ann Allergy Asthma Immunol. 1997;78:457–464
  56. Briggs CG, Freeman RK, Yaffe SJ. Salmeterol. In:  Briggs GG,  Freeman RK,  Yaffe SJ editor. Drugs in pregnancy and lactation. 8th ed.. Philadelphia: Lippincott, Williams, and Wilkins; 2008;p. 1645–1647
  57. Leveno KJ, Little BB, Cunningham FG. The national impact of ritodrine hydrochloride for inhibition of preterm labor. Obstet Gynecol. 1990;76:12–15
  58. Beall MH, Edgar BW, Paul RH, Smith-Wallace T. A comparison of ritodrine, terbutaline, and magnesium sulfate for the suppression of preterm labor. Am J Obstet Gynecol. 1985;153:854–859
  59. Caritis SN, Toig G, Heddinger LA, Ashmead G. A double-blind study comparing ritodrine and terbutaline in the treatment of preterm labor. Am J Obstet Gynecol. 1984;150:7–14
  60. Besinger RE, Niebyl JR. The safety and efficacy of tocolytic agents for the treatment of preterm labor. Obstet Gynecol Surv. 1990;45:415–440
  61. Spellacy WN, Cruz AC, Birk SA, Buhi WC. Treatment of premature labor with ritodrine: a randomized controlled study. Obstet Gynecol. 1979;5:220–223
  62. Larsen JF, Eldon K, Lange AP, et al. Ritodrine in the treatment of preterm labor: Second Danish Multicenter Study. Obstet Gynecol. 1986;67:607–613
  63. Wesselius-de Casparis A, Thiery M, Yo le Sian A, et al. Results of double-blinded, multicentre study with ritodrine in preterm labour. BMJ. 1971;3:144–147
  64. Berkman ND, Thorp JM, Lohr KN, et al. Tocolytic treatment for the management of preterm labor: a review of the evidence. Am J Obstet Gynecol. 2003;188:1648–1659
  65. The Canadian Preterm Labor Investigation Group. Treatment of preterm labor with the beta-adrenergic agonist ritodrine. N Engl J Med. 1992;327:308–312
  66. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 43: management of preterm labor. Obstet Gynecol. 2003;101:1039–1047
  67. Wenstrom KD, Weiner CP, Merrill D, Niebyl J. A placebo-controlled randomized trial of the terbutaline pump for prevention of preterm delivery. Am J Perinatol. 1997;14:87–91
  68. Guinn DA, Goepfert AR, Owen J, Wenstrom KD, Hauth JC. Terbutaline pump maintenance therapy for prevention of preterm delivery: a double-blind trial. Am J Obstet Gynecol. 1998;179:874–878
  69. Nanda K, Cook LA, Gallo MF, Grimes DA. Terbutaline pump maintenance therapy after threatened preterm labor for preventing preterm birth. Cochrane Database Syst Rev. 2002;4:CD003933
  70. Agency for Healthcare Research and Quality (AHRQ). Systemic review of the literature regarding the management of preterm labor: summary, evidence report/technical assessment, no. 18. Rockville, MD: Agency for Healthcare Research and Quality; 2000;
  71. Perry KG, Morrison JC, Rust OA, Sullivan CA, Martin RW, Naef RW. Incidence of adverse cardiopulmonary effects with low-dose continuous terbutaline infusion. Am J Obstet Gynecol. 1995;173:1273–1277
  72. Elliott JP, Istwan NB, Rhea D, Stanziano G. The occurrence of adverse events in women receiving continuous subcutaneous terbutaline therapy. Am J Obstet Gynecol. 2004;191:1277–1282
  73. Quinn PG, Sherman BW, Tavill AS, Gibes AL. Terbutaline hepatitis pregnancy report of two cases and literature review. Am J Gastroenterol. 1994;89:781–784
  74. Hudgens DR, Conrad SE. Sudden death associated with terbutaline sulfate administration. Am J Obstet Gynecol. 1993;169:120–121
  75. Regenstein AC, Belluomini J, Katz M. Terbutaline tocolysis and glucose intolerance. Obstet Gynecol. 1993;81:739–741
  76. Lindenbaum C, Ludmin J, Teplick FB, Cohen AW, Samuels P. Maternal glucose intolerance and the subcutaneous terbutaline pump. Am J Obstet Gynecol. 1993;166:925–928
  77. Fletcher SI, Fyfe DA, Case CL, Wiles HB, Upshur JK, Newman RB. Myocardial necrosis in a newborn after long-term maternal subcutaneous terbutaline infusion for suppression of preterm labor. Am J Obstet Gynecol. 1991;165:1401–1404
  78. Fox NS, Gelber SE, Kalish RB, Chase ST. Contemporary practice patterns and beliefs regarding tocolysis among US maternal-fetal medicine specialists. Obstet Gynecol. 2008;112:42–47
  79. Brown SM, Tejani NA. Terbutaline sulfate in the prevention of recurrence of premature labor. Obstet Gynecol. 1981;57:22–25
  80. Lewis R, Mercer BM, Salana M, Walsh MA, Sibas BM. Oral terbutaline after parenteral tocolysis: a randomized, double-bind, placebo-controlled trial. Am J Obstet Gynecol. 1996;175:834–837
  81. Dodd JM, Crowther CA, Dare MR, Middleton P. Oral betaminetics for maintenance therapy after threatened preterm labor. Cochrane Database of Syst Rev. 2006;I:CD003927
  82. Humphrey M, Chang A, Gilbert M, Wood C. The effect of intravenous ritodrine on acid-base status of the fetus during the second stage of labor. BJOG. 1975;82:234–245
  83. Tejani NA, Verma UL, Chatterjec S, Mittelmann S. Terbutaline the management of acute intrapartum fetal acidosis. J Reprod Med. 1983;28:857–861
  84. Ingermarsson I, Arulkumaran S, Ratnam SS. Single injection of terbutaline in term labor: I, effect on fetal pH in cases with prolonged bradycardia. Am J Obstet Gynecol. 1985;153:859–865
  85. Ingermarsson I, Arulkumaran S, Ratnam SS. Single injection of terbutaline in term labor: II, effect on uterine activity. Am J Obstet Gynecol. 1985;153:865–869
  86. Patriarco MS, Viechnicki BM, Hutchinson TA, Klasko SK, Yeh SY. A study on intrauterine fetal resuscitation with terbutaline. Am J Obstet Gynecol. 1987;157:384–387
  87. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 70: intrapartum fetal heart rate monitoring. Obstet Gynecol. 2005;106:1453–1461

 Reprints not available from the authors.

 Authorship and contribution to the article is limited to the 4 authors indicated. There was no outside funding or technical assistance with the production of this article.

PII: S0002-9378(09)00776-5

doi: 10.1016/j.ajog.2009.07.010

American Journal of Obstetrics & Gynecology
Volume 201, Issue 6 , Pages 553-559 , December 2009

Article Tools